Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030594313> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W3030594313 endingPage "7017" @default.
- W3030594313 startingPage "7017" @default.
- W3030594313 abstract "7017 Background: There are no established methods for pancreatic cancer (PC) screening, but the National Cancer Institute and the Pancreatic Cancer Action Network (PanCAN) are investigating risk-based screening strategies in new-onset diabetes (NOD)—a group with elevated PC risk. Preliminary estimates of the cost-effectiveness of these strategies can provide insights about potential value and inform supplemental data collection. Using data from the Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) risk model validation study, we assessed the potential value of CT screening for PC in those determined to be at elevated PC risk, as is being done in a planned PanCAN Early Detection Initiative (EDI) trial. Methods: We created an integrated decision tree and Markov state-transition model to assess the cost-effectiveness of screening those age ≥50 and with NOD for PC using CT imaging vs. no screening. PC prevalence, sensitivity, and specificity were derived from the ENDPAC validation study. PC stage distribution in the no screening strategy and PC survival were derived from SEER. Background mortality for diabetics, screening and cancer care expenditure, and health state utilities were derived from the literature. The base case assumed 40% of screen-detected PC cases were resectable, and a threshold analysis explored the fraction required for screening to be <$100,000 per QALY gained. Life years (LYs), quality-adjusted life years (QALYs), and costs were tracked over a lifetime horizon and discounted at 3% per year. Results are presented in 2019 USD, and we took a U.S. payer perspective. Results: In the base case, screening resulted in 0.0055 more LYs, 0.0045 more QALYs, and $305 in additional expenditure for a cost per QALY gained of $68,059 (Table). Among PC cases, screening resulted in 0.67 more LYs, 0.55 more QALYs, and $22,691 in additional expenditure. In probabilistic analyses, screening resulted in a cost per QALY gained of <$50,000 and <$100,000 in 34% and 99% of simulations, respectively. In the threshold analysis, >25% of screen-detected cases needed to be resectable for the cost per QALY gained with screening to be <$100,000. Conclusions: We found that risk-based pancreatic cancer screening in NOD is likely to be cost-effective in the U.S. if even a modest fraction (>25%) of screen-detected cases are resectable. Future studies should reassess the value of this intervention once PanCAN EDI data become available. [Table: see text]" @default.
- W3030594313 created "2020-06-05" @default.
- W3030594313 creator A5011046280 @default.
- W3030594313 creator A5048460582 @default.
- W3030594313 creator A5050118261 @default.
- W3030594313 creator A5058030955 @default.
- W3030594313 creator A5074346702 @default.
- W3030594313 creator A5080017108 @default.
- W3030594313 date "2020-05-20" @default.
- W3030594313 modified "2023-10-01" @default.
- W3030594313 title "The potential cost-effectiveness of a risk-based pancreatic cancer screening strategy in new-onset diabetes." @default.
- W3030594313 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.7017" @default.
- W3030594313 hasPublicationYear "2020" @default.
- W3030594313 type Work @default.
- W3030594313 sameAs 3030594313 @default.
- W3030594313 citedByCount "1" @default.
- W3030594313 countsByYear W30305943132021 @default.
- W3030594313 crossrefType "journal-article" @default.
- W3030594313 hasAuthorship W3030594313A5011046280 @default.
- W3030594313 hasAuthorship W3030594313A5048460582 @default.
- W3030594313 hasAuthorship W3030594313A5050118261 @default.
- W3030594313 hasAuthorship W3030594313A5058030955 @default.
- W3030594313 hasAuthorship W3030594313A5074346702 @default.
- W3030594313 hasAuthorship W3030594313A5080017108 @default.
- W3030594313 hasConcept C112930515 @default.
- W3030594313 hasConcept C121608353 @default.
- W3030594313 hasConcept C126322002 @default.
- W3030594313 hasConcept C134018914 @default.
- W3030594313 hasConcept C143998085 @default.
- W3030594313 hasConcept C2780210213 @default.
- W3030594313 hasConcept C3019080777 @default.
- W3030594313 hasConcept C555293320 @default.
- W3030594313 hasConcept C64332521 @default.
- W3030594313 hasConcept C71924100 @default.
- W3030594313 hasConceptScore W3030594313C112930515 @default.
- W3030594313 hasConceptScore W3030594313C121608353 @default.
- W3030594313 hasConceptScore W3030594313C126322002 @default.
- W3030594313 hasConceptScore W3030594313C134018914 @default.
- W3030594313 hasConceptScore W3030594313C143998085 @default.
- W3030594313 hasConceptScore W3030594313C2780210213 @default.
- W3030594313 hasConceptScore W3030594313C3019080777 @default.
- W3030594313 hasConceptScore W3030594313C555293320 @default.
- W3030594313 hasConceptScore W3030594313C64332521 @default.
- W3030594313 hasConceptScore W3030594313C71924100 @default.
- W3030594313 hasIssue "15_suppl" @default.
- W3030594313 hasLocation W30305943131 @default.
- W3030594313 hasOpenAccess W3030594313 @default.
- W3030594313 hasPrimaryLocation W30305943131 @default.
- W3030594313 hasRelatedWork W2022229528 @default.
- W3030594313 hasRelatedWork W2026105846 @default.
- W3030594313 hasRelatedWork W2029073387 @default.
- W3030594313 hasRelatedWork W2077984932 @default.
- W3030594313 hasRelatedWork W2346894020 @default.
- W3030594313 hasRelatedWork W2797250355 @default.
- W3030594313 hasRelatedWork W2899615166 @default.
- W3030594313 hasRelatedWork W2912565296 @default.
- W3030594313 hasRelatedWork W3030594313 @default.
- W3030594313 hasRelatedWork W3217787707 @default.
- W3030594313 hasVolume "38" @default.
- W3030594313 isParatext "false" @default.
- W3030594313 isRetracted "false" @default.
- W3030594313 magId "3030594313" @default.
- W3030594313 workType "article" @default.